Ocugen (OCGN) Non Operating Income (2014 - 2026)
Ocugen posted quarterly Non Operating Income of -$1.3 million for Q1 2026, down 2158.46% year-on-year from $65000.0 in Q1 2025, and down 380.5% on a QoQ basis from $477000.0 in Q4 2025.
Ocugen (OCGN) has 13 years of Non Operating Income data on file, last reported at -$1.3 million in Q1 2026.
- For the quarter ending Q1 2026, Non Operating Income fell 2158.46% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$2.1 million (down 694.62% YoY), and the FY2025 full-year result was -$664000.0, down 574.29% from the prior year.
- Non Operating Income for Q1 2026 stood at -$1.3 million, down from $477000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.2 million in Q3 2022 and bottomed at -$1.3 million in Q1 2026.
- The 5-year median for Non Operating Income is $114000.0 (2025), against an average of $140235.3.
- The widest annual swing landed in 2022, when Non Operating Income jumped 10777.78%; it then sank 2158.46% in 2026.
- A 5-year view of Non Operating Income shows it stood at $961000.0 in 2022, then slumped by 42.25% to $555000.0 in 2023, then plunged by 208.65% to -$603000.0 in 2024, then surged by 179.1% to $477000.0 in 2025, then plunged by 380.5% to -$1.3 million in 2026.
- The last three Non Operating Income figures came in at -$1.3 million (Q1 2026), $477000.0 (Q4 2025), and -$1.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Ocugen | 452.01 Mn | 452.01 Mn | - | -1.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.34 Mn |
| Dec 31, 2025 | 477,000.00 |
| Sep 30, 2025 | -1.32 Mn |
| Jun 30, 2025 | 114,000.00 |
| Mar 31, 2025 | 65,000.00 |
| Dec 31, 2024 | -603,000.00 |
| Sep 30, 2024 | 282,000.00 |
| Jun 30, 2024 | -4,000.00 |
| Mar 31, 2024 | -10,000.00 |
| Dec 31, 2023 | 555,000.00 |
| Sep 30, 2023 | 714,000.00 |
| Jun 30, 2023 | 475,000.00 |
| Mar 31, 2023 | 709,000.00 |
| Dec 31, 2022 | 961,000.00 |
| Sep 30, 2022 | 1.20 Mn |
| Jun 30, 2022 | 94,000.00 |
| Mar 31, 2022 | 15,000.00 |
| Dec 31, 2021 | -9,000.00 |
| Sep 30, 2021 | -18,000.00 |
| Jun 30, 2021 | -342,000.00 |
| Mar 31, 2021 | -20,000.00 |
| Dec 31, 2020 | 739,000.00 |
| Jun 30, 2020 | -248,000.00 |
| Mar 31, 2020 | -15,000.00 |
| Dec 31, 2019 | -32,507.00 |
| Sep 30, 2019 | -20.06 Mn |
| Jun 30, 2019 | 184.00 |
| Mar 31, 2019 | -1.47 Mn |
| Dec 31, 2018 | -10,015.00 |
| Sep 30, 2018 | 471,844.00 |
| Jun 30, 2018 | 3.51 Mn |
| Mar 31, 2018 | -8.74 Mn |
| Dec 31, 2017 | 26,000.00 |
| Sep 30, 2017 | -282,000.00 |
| Jun 30, 2017 | -73,000.00 |
| Mar 31, 2017 | -17,000.00 |
| Dec 31, 2016 | 2.62 Mn |
| Sep 30, 2016 | -2.67 Mn |
| Jun 30, 2016 | -66,000.00 |
| Mar 31, 2016 | -101,000.00 |
| Dec 31, 2015 | 98,000.00 |
| Sep 30, 2015 | -16,000.00 |
| Jun 30, 2015 | -40,000.00 |
| Mar 31, 2015 | -29,000.00 |
| Dec 31, 2014 | -2.40 Mn |
| Sep 30, 2014 | 2.97 Mn |
| Jun 30, 2014 | -3,000.00 |
| Mar 31, 2014 | -2,000.00 |